Israel
Industry
Leading generic drugmaker Teva has posted a strong set of financial results for Q210, with sales increasing by 11.76% to US$3.8bn from US$3.4bn in Q209. Operating profit figures for...
2010-07-28Industry
Israeli generic drugmaker Teva has released its Q110 financial results, with a year-on-year (y-o-y) gross profit rise of 28% to US$2.01bn. The recent acquisition of German Ratiopharm...
2010-05-05Industry
Israeli drugmaker Rafa Laboratories' recent decision to gradually move away from being a generic drugmaker and begin investing in the research and development (R&D) of patented...
2010-04-22Industry
Teva's recent acquisition of Ratiopharm underlined our expectations for the firm in terms of both its current growth strategy and its geographic expansion plans. BMI also expects...
2010-04-14Industry
The US has signed an agreement with the Israeli government that will later see the Middle Eastern country removed from the US Trade Representative (USTR)'s Priority Watch List - part...
2010-03-08Industry
Israeli generic drugmaker Teva has received a US$2.5mn investment offer from GlaxoSmithKline (GSK) into Proteologics, which accounts for 7% of its shares. GSK has decided to pay in...
2010-02-23Industry
Israeli generic drugmaker Teva has announced its full-year unaudited financial results, with a profitable Q409 pushing sales above 2008 levels. BMI believes much of the firm's...
2010-02-17Industry
In a recent investor presentation, Teva announced that it plans to generate revenues of around US$31bn by 2015 in line with its more broadly optimistic outlook for an increase in...
2010-01-08
